70 results about "Lung cancer screening" patented technology

The invention discloses a deep convolutional neural network-based lung cancer preventing self-service health cloud service system. The system comprises a convolutional neural network used for deep learning and training identification, a segmentation module which segments out a lung region from a CT image based on a full convolutional neural network, a deep convolutional neural network used for lung cancer diagnosis classification, and a self-service health cloud service platform used for performing early prevention and treatment according to an identified suspected lung cancer type. According to the system, the automation and intelligentization level of mobile internet-based lung cancer screening can be effectively improved, more citizens can know and participate in self-service health detection, assessment and guidance, the sensitivity, specificity and accuracy of early lung cancer screening and clinical diagnosis are improved, the lung cancer can be early discovered, early diagnosed and early treated, and the self-health management capability is enhanced.

A method, system, and computer program product for detecting at least one nodule in a medical image of a subject, including identifying, in the medical image, an anatomical region corresponding to at least a portion of an organ of interest; filtering the medical image to obtain a difference image; detecting, in the difference image, a first plurality of nodule candidates within the anatomical region; calculating respective nodule feature values of the first plurality of nodule candidates based on pixel values of at least one of the medical image and the difference image; removing false positive nodule candidates from the first plurality of nodule candidates based on the respective nodule feature values to obtain a second plurality of nodule candidates; and determining the at least one nodule by classifying each of the second plurality of nodule candidates as a nodule or a non-nodule based on at least one of the pixel values and the respective nodule feature values. True-positive nodules are identified using linear discriminant analysis and/or a Multi-MTANN.

The invention relates to the technical field of medical diagnostics, in particular to the field of tumor diagnosis. By analyzing the concentration of small-molecule metabolites in blood of a normal person, blood of a person before a lung cancer operation is carried out, and blood of a person after the lung cancer operation is carried out, multiple metabolism markers which can be used for monitoring the lung cancer curative effect and multiple metabolism markers which can be used for lung cancer diagnosis are screened out. The method has the advantages of being high in sensitivity and flux, and applicable to lung cancer screening and auxiliary diagnosis.

The invention provides a composition for lung cancer screening. The composition consists of nucleotide sequences for detecting a methylation degree in at least one target region of each of the following genes: an SHOX2 gene, a PTGER4 gene and an FOXL2 gene, wherein the target regions are continuous segments which are selected from SEQ ID NO: 25, SEQ ID NO: 26 and SEQ ID NO: 27 and are at least 18 bases in length; and the nucleotide sequences are equivalent, complementary or hybridized in the target regions. With the application of the composition disclosed by the invention, the existence of cell hyperplastic abnormity can be shown by integrating methylation detection results of the SHOX2, the PTGER4 and the FOXL2.

The invention discloses a lung cancer screening method based on a neural network, and the method comprises the steps: data preparation: mainly completing the importing of data from a hospital data system and the calibration of data at the stage; preprocessing of the data, namely preprocessing the data and segmenting a lung region in the stage; constructing and training of a three-dimensional RPN network, namely training the RPN network by using the acquired data and the calibration result; training networks suitable for different resolutions, and constructing a combination strategy; carrying out pulmonary nodule detection on the input three-dimensional CT image by using the trained model, and outputting predicted pulmonary nodule information including a central point three-dimensional coordinate and the diameter of the pulmonary nodule; constructing a neural network based on an attention mechanism according to the three-dimensional coordinates and the diameter of the central point given in the step 5, and judging the property of the pulmonary nodule. According to the method, candidate nodule detection is directly carried out on three-dimensional input, so that candidate detection is more comprehensive and reliable.

A method for identifying micro ribonucleic acid (RNA) in the blood serum of a lung cancer patient through Solexa technology belongs to the biological medicine technical field, in particular relating to a Solexa technology for measuring the expression of micro RNA in the blood serum of a lung cancer patient as well as an application of the Solexa technology in clinic diagnosis and therapy such as early diagnosis of lung cancer, curative effect appraisement and drug effect appraisement, etc. The Solexa technology comprises the following steps that: a Solexa sequencing method is used to measure the content of micro RNA in the blood serum of a lung cancer testee; the appraisement of the physiological and/or pathological status of the testee is to carry out lung cancer diagnosis of the testee; and the physiological and/or pathological status of the testee is tested after the testee receives a to-be-tested object. The Solexa sequencing method has the advantages of wide detection pedigree, high sensitivity, low detection cost, convenient material obtaining and easily stored samples, etc.; moreover, the method can be widely used in related operations including lung cancer screening, etc. so as to improve the conditions of low specificity and low sensitivity caused by individual difference which is difficult to be overcome by a single marker; therefore, the method can substantially increase the clinic detection rate of lung cancer, and is an effective way to carry out early diagnosis of lung cancer.

The invention discloses a big data based lung cancer screening system and method. The system includes a collection terminal, a server and a man-machine interface. The collection terminal collects dataof lung cancer patients and detection data of patients that need to be screened and uploads all the data. The server is used for receiving the data and the detection data, establishing a lung cancerpatient database on the basis of the data, conducting data analysis on the lung cancer patient database, obtaining relation data between the lung cancer and pathogenic factors, learning and training the relation data to obtain a lung cancer risk predication model, processing the detection data through the lung cancer risk predication model, obtaining reference data between pathogenic factors of the patients that need to be screened and the lung cancer, and sending the reference data to a man-machine interface for display. The beneficial effects are that the relation data of different pathogenic factors and the lung cancer are obtained by conducting big data analysis and counting on the database of the lung cancer patients, so a scientific reference basis is provided for early-stage screening of the lung cancer.

The invention discloses a lung cancer screening kit, comprising an optional reagent for detecting the expression level of fatty acid binding protein 1 (FABP1). The invention also discloses use of the reagent for detecting the expression level of the FABP1 in preparation of a lung cancer screening reagent. The lung cancer screening kit is capable of being used for judging the risk of lung cancer of people to be detected by detecting the expression level of the FABP1, thus being used for auxiliary diagnosis of clinical lung cancer; the lung cancer screening kit provides an effective basis for taking relevant treatment measures or decisions to a patient; the lung cancer screening kit has good clinical application prospect.

The invention relates to the field of image analysis, and particularly relates to an early lung cancer detection and classification integrated system based on deep learning. The system comprises a lung CT image acquisition module, a CT image preprocessing module, a lung image recognition module, a lung nodule measurement module and a lung cancer screening module. The lung image recognition moduledetects and recognizes lung nodules and lung nodule holes in the lung images based on a DSSD_ Xception model, and intercepts lung nodule areas; the lung nodule measurement module is used for measuringlung nodules and lung nodule hole sizes based on the length-width ratio of the connected component bounding rectangle, and outputting a measurement result; and the lung cancer screening module is used for screening early lung cancer based on a preset screening standard according to the measurement result of the lung nodule. According to the invention, the type and probability of early lung cancercan be automatically detected, and the type, size, position and malignant degree of pulmonary nodules can be accurately identified.

The invention relates to lung cancer preventing and treating composition extracted from selfheal and/or garden orache and application thereof in preparation of lung cancer preventing and treating medicine. The composition comprises phenolic acid component, flavone component and triterpene component and is characterized in that the weight ratio of the phenolic acid component, flavone component and triterpene component is 5-70: 2-60: 0.5-40. In optimum proposal, the phenolic acid component takes caffeic acid and rosmarinic acid as typical ingredients; the flavone component takes rutin and quercetin as typical ingredients; the triterpene component takes ursolic acid and oleanolic acid as typical ingredients; the weight ratio of the caffeic acid, rosmarinic acid, rutin, quercetin, ursolic acid and oleanolic acid is 0-20: 5-50: 2-40: 0-20: 0.25-20: 0.25-20. The invention overcomes the defect of control is difficult in the prior art, active component is separated, purified and enriched, process is simple; preventing and treating activity on lung cancer and related diseases is strong; and mass production can be carried out.

The invention belongs to the technical field of molecular biology and clinical detection, and relates to a protein composition containing any two, three, four, five, six or seven selected from the group consisting of CYFRA21-1, NSE, IL-2, IL-8, IFN-gamma, MIP-1beta and VEGF-A. The invention also relates to a ligand composition that binds to the protein specificity in the protein composition, and application of the protein composition or ligand composition in the preparation of a kit for screening, auxiliary diagnosis, treatment monitoring and prognosis of lung cancer. The invention can be usedfor screening, auxiliary diagnosis, treatment monitoring and prognosis judgment of lung cancer, especially screening and auxiliary diagnosis of early lung cancer, which has high sensitivity and highspecificity, and is superior to the detection of single protein markers and clinical commonly-used serum markers CYFRA21-1 and NSE.

The invention relates to the technical field of biotechnology, in particular to a lung cancer detection kit which takes miR-21 and miR-205 in serum as markers and is used for lung cancer screening and postoperative monitoring. The miR-21 and miR-205 in serum/blood plasma are selected to jointly serve as lung cancer markers, and the lung cancer diagnostic kit which has rapidness and convenience in detection, is high in accuracy and can be used for achieving lung cancer early screening and prognostic auxiliary diagnoses is developed through a qRT-PCR method. The kit has rapidness and convenience in detection and is high in detection sensitivity and specificity and low in cost, can meet the early screening and prognosis judgment detection requirements of a majority of cancer patients, is extremely wide in application range, and is high in accuracy according to clinical verification prediction. The detection sensitivity of the kit in distinguishing lung cancer samples and samples of able-bodied persons is 96.3%, and the specificity is 89.7%.

The invention provides application of a fungal microbiome as a marker in preparation, treatment, screening and lung cancer diagnosis. By constructing a fungal microbiome DNA enrichment and extractionmethod, fungal microbiome DNA is extracted from tissues, feces and alveolar lavage fluid, and ITS sequencing and metagenome sequencing are applied to fungal microbiome and gene function analysis, wherein aspergillus polyangius is enriched in tumor tissues, candida albicans is enriched in tumor tissues and para-carcinoma tissues, and malassezia is enriched in alveolar lavage fluid; by detecting these target strains or molecular markers, lung cancer can be found and intervened as early as possible, and the target strains or molecular markers are expected to be used as important indicators for lung cancer screening; and in addition, the characteristics of the type and quantity of fungi are obtained through DNA sequencing results of fungal florae in feces, tissues and alveolar lavage fluid samples of different parts of lung adenocarcinoma patients, and the lung cancer is more accurately screened and diagnosed in an assisted mode based on the quantity and ratio characteristics of the fungispecifically enriched in the lung cancer.

The invention discloses a joint detection kit for miRNA marker of lung cancer. The joint detection kit comprises reverse transcription primers shown as SEQ ID NO.1 to 2 as well as primer pairs shown as SEQ ID NO.3 to 4 and SEQ ID NO.5 to 6. The invention also discloses application of the reverse transcription primers shown as SEQ ID NO.1 to 2 as well as the primer pairs shown as SEQ ID NO.3 to 4 and SEQ ID NO.5 to 6 in preparation of reagents for screening the lung cancer. The joint detection kit disclosed by the invention can be used for screening of the lung cancer and clinical auxiliary diagnosis of the lung cancer and has the advantages of high detection sensitivity, good specificity a good clinical application prospect.

The invention belongs to the technical field of data analysis, and discloses a method and a system for constructing a pulmonary nodule database and a prediction model based on a column diagram. The method comprises the steps of collecting LDCT features and clinical related information of benign and malignant pulmonary nodule patients with clear pathological diagnosis to construct a benign and malignant pulmonary nodule database; incorporating a plurality of LDCT indexes and serum CEA levels into a Logistic regression model by adopting an entry method, and forming a pulmonary nodule malignant prediction model; and performing external verification on the constructed pulmonary nodule malignant prediction model. The invention provides an effective and practical malignant pulmonary nodule prediction model jointly applying the LDCT index and the serum CEA level, the malignant probability of the pulmonary nodule can be accurately predicted, and a basis is provided for rapid and reasonable clinical management and effective clinical treatment of a pulmonary nodule patient. The method overcomes the problems of high LDCT false positive rate in lung cancer screening and insufficient sensitivity and specificity in individual application of tumor markers.

The invention provides a lung cancer screening kit, which is a kit for detecting ZNF808 gene methylation of lung tissue. The invention also provides application of a reagent for detecting ZNF808 genemethylation in preparation of a lung cancer screening reagent. The kit can be used for auxiliary diagnosis of clinical lung cancer, provides an effective basis for patients to take related treatment measures or make decisions and has a good clinical application prospect.

The invention relates to the technical field of lung cancer tumor screening and particularly relates to a lung cancer screening system based on big data. The system comprises a central server, networknodes connected with the central server through a network, and portable monitoring devices in network connection with the central server, wherein each network node is connected with a hospital data platform in an area, the hospital data platform transmits the diagnosis information of a patient to the central server in real time through the network nodes, and the portable monitoring devices are worn on bodies of patients and arranged around the patients. The system is advantaged in that preliminary screening of lung cancer can be performed on a large number of users in the earlier stage, high-risk users are reminded to go to a hospital for definite diagnosis, on one hand, a lung cancer screening range is expanded, on the other hand, cost is saved through grading screening, so medical resources are used more effectively, moreover, canceration possibility prediction is carried out on the patients suffering from lung diseases, and lung cancer is restrained in the early stage of cancer intime.

The present invention discloses a lung cancer screening kit comprising an optional reagent for detecting the expression level of p-ZAP70. The present invention also discloses use of the reagent for detecting the expression level of the p-ZAP70 in the preparation of a reagent for screening for lung cancer. The kit can determine the risk of lung cancer among subjects by detecting the expression level of the pZAP70, can be used for auxiliary diagnosis of clinical lung cancer, provides patients an effective basis for relevant therapeutic measures or decisions, and has good clinical application prospects.

The invention discloses application of a gene marker combination in lung cancer screening and prognosis judgment. The gene marker can effectively diagnose lung cancer and reduce the omission factor oflung cancer, is very beneficial to early diagnosis and early treatment of lung cancer, is greatly helpful for improving lung cancer prognosis and reducing the death rate of lung cancer, and has goodclinical application and popularization values.

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a CETP detection reagent in preparation of a lung cancer screening kit. What is found for the firsttime is that the level of CETP protein in plasma exosomes of lung cancer patients is significantly higher than that of CETP protein in healthy people. The reagent for detecting the CETP protein is used for preparing the lung cancer screening kit, and effective screening of lung cancer can be achieved.